The company has not filed an annual or quarterly report since its Q3 FY2024 10-Q, filed Nov 7, 2024. Its latest SEC filing is a 15-12G from Nov 25, 2024.
10-Q for Q3 FY2024, filed Nov 7, 2024
The sections below describe the company as of the FY2023 annual report.
Develops and sells implanted nerve-stimulation systems to treat bladder and bowel dysfunction in adults. Also sells a urethral gel to treat stress urinary incontinence in women.
10-K for FY2023, filed Feb 29, 2024We are a global medical technology company that develops and commercializes innovative and minimally invasive products to treat adults with…View ↗
SNM SystemsView ↗
Our newly developed recharge-free sacral neuromodulation (SNM) system, Axonics F15, received FDA approval in March 2022 and utilizes a…View ↗
Our newly developed fourth-generation rechargeable SNM system, Axonics R20, is only 5cc in volume and is designed to last 20 or more years…View ↗
As a next-generation bulking agent, we believe Bulkamid addresses the shortcomings of legacy particulate-based bulking agents. It is a…View ↗
Axonics sells products to customers and distributors; sales occur when the goods are handed over, and payment is typically due within three months.
10-K for FY2023, filed Feb 29, 2024
$366.4M
10-K for FY2023, filed Feb 29, 2024
$366.4M ↗| Segment | Share | Revenue |
|---|---|---|
|
SNM net revenue
|
80%
FY2020: 100%
|
SNM net revenue, FY2023
$291.8M Sources
|
|
Bulkamid net revenue
|
20%
FY2020: 0.0%
|
Bulkamid net revenue, FY2023
$74.6M Sources
|
Its sales team sells directly to urologists, urogynecologists and colorectal surgeons; distributors serve some international markets.
10-K for FY2023, filed Feb 29, 2024Bulkamid received a Conformité Européenne (CE) Mark in 2003 and a PMA from the FDA in 2020 and is sold through a combination of a direct…View ↗
Through our specialized and dedicated direct sales organization, we are targeting urologists, urogynecologists and colorectal surgeons…View ↗
Although our main commercial priority is the United States, in November 2018, we launched a limited commercial effort in Europe. With the…View ↗
No. It lost $6.1M in FY2023.
10-Q for Q3 FY2024, filed Nov 7, 2024
−$21KView ↗
10-Q for Q3 FY2024, filed Nov 7, 2024
Open tableView ↗
8-K, filed Nov 15, 2024
As described in the Introductory Note of this Current Report on Form 8-K, on November 15, 2024, the Merger was completed. Upon the…View ↗
Grew. Revenue grew 26.5x in 4 years, from $13.8M in FY2019 to $366.4M in FY2023, about 127% a year.
Broader implanted therapy lineup
The older report described a rechargeable implanted nerve-stimulation system and listed a non-rechargeable model as a future product goal. The latest report describes both rechargeable and recharge-free systems.
10-K for FY2020, filed Mar 1, 2021 10-K for FY2023, filed Feb 29, 2024
Competes with Medtronic and Allergan
10-K for FY2023, filed Feb 29, 2024We consider our primary competition to be implantable SNM devices offered by Medtronic. Medtronic’s InterStim X and InterStim Micro are…View ↗
Loading...